Caisse de depot et placement du Quebec Makes New Investment in DaVita Inc. $DVA

Key Points

• Caisse de dépôt et placement du Québec purchased 39,200 DaVita shares worth approximately $8.7 million, giving it a 0.06% stake. Institutional investors collectively own 90.12% of the company.
• DaVita exceeded quarterly expectations, reporting $4.02 in earnings per share versus the $3.88 consensus and revenue of $3.55 billion, up 5.2% year over year. The company maintained fiscal 2026 EPS guidance of $14.10–$15.20.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and a $221.75 price target; four analysts rate the stock Buy, three Hold, and one Sell.

Caisse de depot et placement du Quebec purchased a new stake in DaVita Inc. (NYSE:DVA - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 39,200 shares of the company's stock, valued at approximately $8,721,000. Caisse de depot et placement du Quebec owned about 0.06% of DaVita at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Root Financial Partners LLC boosted its stake in shares of DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company's stock valued at $29,000 after purchasing an additional 105 shares during the last quarter. Caitlin John LLC bought a new position in DaVita during the fourth quarter worth $34,000. Sankala Group LLC acquired a new position in DaVita in the fourth quarter valued at $39,000. Canada Pension Plan Investment Board bought a new stake in DaVita during the second quarter valued at $43,000. Finally, Kestra Advisory Services LLC acquired a new stake in DaVita during the 4th quarter worth about $45,000. 90.12% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the firm's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares of the company's stock, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.90% of the company's stock.

DaVita Trading Up 1.0%

Shares of NYSE DVA opened at $180.72 on Friday. The firm has a market capitalization of $11.53 billion, a P/E ratio of 14.79, a P/E/G ratio of 0.47 and a beta of 0.88. The firm's 50-day moving average price is $211.96 and its 200-day moving average price is $183.05. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. During the same period last year, the business posted $2.95 EPS. The firm's revenue for the quarter was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts forecast that DaVita Inc. will post 14.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Oppenheimer set a $220.00 price objective on DaVita in a research note on Friday, August 7th. Barclays raised their target price on DaVita from $218.00 to $224.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 5th. TD Cowen raised DaVita from a "hold" rating to a "buy" rating and boosted their price target for the company from $201.00 to $220.00 in a research note on Friday, August 7th. Raymond James Financial set a $220.00 price target on DaVita in a report on Friday, August 7th. Finally, Zacks Research downgraded shares of DaVita from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 6th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, DaVita presently has a consensus rating of "Hold" and a consensus price target of $221.75.

DaVita Profile

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.